Latest market price
9.05
-0.44-4.64%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -2.34 | Insider Own | — | Shs Outstand | 23.92M | Perf Week | -9.32% |
| Market Cap | 216.49M | Forward P/E | — | EPS next Y | -0.70 | Insider Trans | -0.00% | Shs Float | 14.54M | Perf Month | -14.22% |
| Enterprise Value | 73.49M | PEG | — | EPS next Q | -0.65 | Short Float | 6.00% | Perf Quarter | -33.99% | ||
| Income | -207.00M | P/S | 56.21 | EPS this Y | — | Short Ratio | 2.51 | Perf Half Y | -53.52% | ||
| Sales | 0.00 | P/B | 1.45 | EPS next Y | — | ROA | -98.27% | Short Interest | 872.08K | Perf YTD | -52.79% |
| Book/sh | 6.23 | P/C | 1.30 | EPS next 5Y | — | ROE | -121.83% | 52W High | 26.19 -65.44% | Perf Year | -35.77% |
| Cash/sh | 6.94 | P/FCF | — | EPS past 3/5Y | — | ROIC | -123.37% | 52W Low | 8.63 4.87% | Perf 3Y | -16.20% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | -110.70% | Volatility | 8.42% 5.47% | Perf 5Y | -82.36% |
| Dividend TTM | — | EV/Sales | 31.59 | EPS Y/Y TTM | — | Oper. Margin | -3687.06% | ATR (14) | 0.62 | Perf 10Y | -94.91% |
| Dividend Ex-Date | — | Quick Ratio | 3.24 | Sales Y/Y TTM | -100.00% | Profit Margin | -3631.47% | RSI (14) | 35.81 | Recom | 2.40 |
| Dividend Gr. 3/5Y | — | Current Ratio | 3.24 | EPS Q/Q | -104.08% | SMA20 | -5.63% | Beta | -0.76 | Target Price | 46.33 |
| Payout | 0.00% | Debt/Eq | 0.15 | Sales Q/Q | — | SMA50 | -20.74% | Rel Volume | 0.56 | Prev Close | 9.49 |
| Employees | 125 | LT Debt/Eq | 0.05 | Earnings | Mar 25 | SMA200 | -46.46% | Avg Volume | 368.80K | Price | 9.05 |
| IPO Date | Oct 22, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -169.23% 257.07% | Net Debt/EBITDA | — | Volume | 207,358 | Change | -4.64% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Dec-17-25 | Reiterated | Cantor Fitzgerald | Overweight | $42 → $48 |
| Dec-17-25 | Reiterated | Guggenheim | Buy | $35 |
| Dec-17-25 | Reiterated | HC Wainwright & Co. | Buy | $35 → $40 |
| Dec-15-25 | Reiterated | HC Wainwright & Co. | Buy | $16 → $35 |
| Dec-14-25 | Initiated | Cantor Fitzgerald | Overweight | $42 |
| Dec-03-25 | Initiated | Guggenheim | Buy | $35 |
| May-05-25 | Reiterated | HC Wainwright & Co. | Buy | $16 |
| Mar-17-20 | Downgrade | Stifel | Buy → Hold | |
| Jan-09-20 | Upgrade | Stifel | Hold → Buy | |
| Dec-20-18 | Downgrade | Barclays | Overweight → Equal Weight |
Latest News· Times ET
Nov-02-26
Nov-02-2604:30PM
Oct-29-26
Oct-28-26
08:05PM
04:47PM
Oct-27-26
Oct-27-2604:30PM
Oct-22-26
Oct-22-2611:07AM
Oct-17-26
Oct-17-2603:29AM
Oct-16-26
Oct-16-2611:06AM
03:41AM
Oct-12-26
Oct-12-2611:14AM
Oct-08-26
Oct-06-26
Oct-06-2611:11AM
Oct-03-26
Sep-30-26
Company
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 16 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 7 | 0 | — | — | — | — | — | |
| Gross Profit | 0 | 0 | -7 | 16 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 60 | 36 | 24 | 32 | — | — | — | — | — | |
| Research and Development | 144 | 117 | 90 | 60 | — | — | — | — | — | |
| Other Operating Expense | 5 | -6 | 0 | 0 | — | — | — | — | — | |
| Operating Income | -209 | -147 | -121 | -76 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 3 | 1 | 3 | 4 | — | — | — | — | — | |
| Net Income Before Taxes | -206 | -146 | -118 | -73 | — | — | — | — | — | |
| Income Taxes | -1 | 0 | -4 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -207 | -147 | -114 | -73 | — | — | — | — | — | |
| Net Income From Continuing Operations | -207 | -147 | -114 | -73 | — | — | — | — | — | |
| Net Income | -207 | -147 | -114 | -73 | — | — | — | — | — | |
| EPS (Recurring) | -2.34 | -1.70 | -1.20 | -0.75 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.34 | -1.70 | -1.20 | -0.75 | — | — | — | — | — | |
| EPS (Diluted) | -2.34 | -1.70 | -1.20 | -0.75 | — | — | — | — | — | |
| EBITDA | -198 | -144 | -111 | -63 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | 56.70 | — | — | — | — | — | |
| Gross Margin | — | — | — | 100.00 | — | — | — | — | — | |
| Operating Margin | — | — | — | -475.00 | — | — | — | — | — | |
| Net Margin | — | — | — | -456.25 | — | — | — | — | — | |
| Shares Outstanding | 90 | 86 | 96 | 95 | — | — | — | — | — | |
| Market Capitalization | 815 | 1,649 | 297 | 907 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer | Jul 29 '26 | Sale | 2.70 | 464 | 1,253 | 144,531 | Jul 31 |
| Mohideen Pharis | Chief Medical Officer | Jan 29 '26 | Sale | 4.86 | 534 | 2,595 | 144,995 | Feb 02 |
| BAKER BROS. ADVISORS LP | Director | Jan 12 '26 | Option Exercise | 0.00 | 27,304,896 | 0 | 25,005,240 | Jan 14 |
| EPIC Bpifrance | Member of 10% owner group | Dec 18 '25 | Sale | 4.19 | 1,292,103 | 5,413,912 | 7,303,369 | Dec 19 |
| EPIC Bpifrance | Member of 10% owner group | Dec 17 '25 | Sale | 4.85 | 2,076,990 | 10,070,232 | 8,595,472 | Dec 19 |
| Mohideen Pharis | Chief Medical Officer | Nov 21 '25 | Sale | 2.77 | 1,624 | 4,498 | 101,529 | Nov 25 |
| Mohideen Pharis | Chief Medical Officer | Nov 20 '25 | Sale | 2.88 | 6,496 | 18,708 | 103,153 | Nov 25 |
| Mohideen Pharis | Chief Medical Officer | Jul 29 '25 | Sale | 2.22 | 464 | 1,030 | 109,649 | Jul 31 |
| Mohideen Pharis | Chief Medical Officer | May 22 '25 | Sale | 1.84 | 397 | 730 | 110,113 | May 27 |
| Mohideen Pharis | Chief Medical Officer | Jan 30 '25 | Sale | 0.85 | 600 | 510 | 110,510 | Jan 31 |
| Mohideen Pharis | Chief Medical Officer | Nov 25 '24 | Sale | 0.57 | 565 | 322 | 111,110 | Nov 27 |
| Mohideen Pharis | Chief Medical Officer | Nov 22 '24 | Sale | 0.53 | 342 | 181 | 111,675 | Nov 27 |
| Mohideen Pharis | Chief Medical Officer | Nov 21 '24 | Sale | 0.54 | 2,350 | 1,269 | 112,017 | Nov 25 |
| Mohideen Pharis | Chief Medical Officer | Jul 29 '24 | Sale | 0.98 | 1,785 | 1,749 | 79,367 | Jul 31 |
| Mohideen Pharis | Chief Medical Officer | May 24 '24 | Sale | 1.36 | 660 | 898 | 81,152 | May 29 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.